CEACAM5 and neoplasm: Identifying well-known tumor biomarkers, such as prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), and cancer antigen 125 (CA 125) in precancers and early stages is uncertain, and even if present, they lack high specificity and sensitivity [26].